BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29794421)

  • 1. Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
    Gong S; Xu D; Zhu J; Zou F; Peng R
    Cell Physiol Biochem; 2018; 47(2):680-693. PubMed ID: 29794421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.
    Sriraman SK; Geraldo V; Luther E; Degterev A; Torchilin V
    J Control Release; 2015 Dec; 220(Pt A):160-168. PubMed ID: 26497930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate.
    Zhang X; Min KW; Wimalasena J; Baek SJ
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2051-60. PubMed ID: 22814742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
    Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
    Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baicalein Inhibits Proliferation Activity of Human Colorectal Cancer Cells HCT116 Through Downregulation of Ezrin.
    Chen Z; Hou R; Gao S; Song D; Feng Y
    Cell Physiol Biochem; 2018; 49(5):2035-2046. PubMed ID: 30244250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of REG Iα Enhances the Sensitivity to 5-Fluorouracil of Colorectal Cancer Cells via Cyclin D1/CDK4 Pathway and BAX/BCL-2 Pathways.
    Wang Y; Liu X; Liu J; Zhang T
    Cancer Biother Radiopharm; 2019 Aug; 34(6):362-370. PubMed ID: 30973271
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1.
    Chen C; Chang YC; Liu CL; Chang KJ; Guo IC
    Breast Cancer Res Treat; 2006 Jul; 98(2):121-32. PubMed ID: 16752079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
    Zhang L; Xie D; Lei Y; Na A; Zhu L
    Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
    [No Abstract]   [Full Text] [Related]  

  • 11. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
    Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
    Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment.
    Adamsen BL; Kravik KL; Clausen OP; De Angelis PM
    Int J Oncol; 2007 Dec; 31(6):1491-500. PubMed ID: 17982676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NFE2L3 Inhibition Induces Cell Cycle Arrest at the G0/G1 Phase in Colorectal Cancer Cells through Downregulating CCND1 and pRb1-ser807/811.
    Zhang L; Hu DL; Tang B; Cheng Y; Jiao C; Cheng L; Tan ZR; Zhou HH
    Dis Markers; 2019; 2019():2829798. PubMed ID: 31191746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aloperine induces G2/M phase cell cycle arrest and apoptosis in HCT116 human colon cancer cells.
    Zhang L; Zheng Y; Deng H; Liang L; Peng J
    Int J Mol Med; 2014 Jun; 33(6):1613-20. PubMed ID: 24682388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adiponectin inhibits proliferation and induces apoptosis in colorectal cancer HCT116 cells].
    Huang M; Chen Z; Xu D; Zhang H; Sun S; Wu J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Mar; 34(3):253-259. PubMed ID: 29773108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to 3-HTMC-Induced Apoptosis Through Activation of PI3K/Akt, MEK/ERK, and p38/COX-2/PGE
    Semaan J; Pinon A; Rioux B; Hassan L; Limami Y; Pouget C; Fagnère C; Sol V; Diab-Assaf M; Simon A; Liagre B
    J Cell Biochem; 2016 Dec; 117(12):2875-2885. PubMed ID: 27192488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-carnosine induces apoptosis/cell cycle arrest via suppression of NF-κB/STAT1 pathway in HCT116 colorectal cancer cells.
    Lee J; Park JR; Lee H; Jang S; Ryu SM; Kim H; Kim D; Jang A; Yang SR
    In Vitro Cell Dev Biol Anim; 2018 Aug; 54(7):505-512. PubMed ID: 29869056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells.
    Jang CH; Moon N; Oh J; Kim JS
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pien Tze Huang Inhibits Proliferation of Colorectal Cancer Cells through Suppressing PNO1 Expression and Activating p53/p21 Signaling Pathway.
    Cao LJ; Liu LY; Chen YQ; Han YY; Wei LH; Yao MY; Fang Y; Wu MZ; Cheng Y; Sferra TJ; Liu HX; Li L; Peng J; Shen AL
    Chin J Integr Med; 2024 Jun; 30(6):515-524. PubMed ID: 38216838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.